Rodman & Renshaw raised its rating on Omeros Corp OMER to Market Outperform from Market Perform and establishes a new price target of $13 per share on the stock based on expected pivotal eye surgery data.
Rodman says, “Pivotal data are expected from the OMS302 Phase 3 clinical program in eye surgery (1Q12), in addition to results from a Phase trial with OMS103HP in knee surgery (mid-2012). We believe that the anticipation of potentially positive news flow could serve as a catalyst on Omeros shares. We are upgrading the stock from Market Perform to Market Outperform with a new 12-month target price of $13/sh.”
OMER closed at $3.93 per share on Friday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in